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Abstract
Levels of exposure to ionizing radiation are increasing for women worldwide due to the
widespread use of CT and other radiologic diagnostic modalities. Exposure to ionizing radiation as
well as increased levels of estradiol and other sex hormones are acknowledged breast cancer risk
factors, but the effects of whole-body radiation on serum hormone levels in cancer-free women are
unknown. This study examined whether ionizing radiation exposure is associated with levels of
serum hormones and other markers that may mediate radiation-associated breast cancer risk.
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Serum samples were measured from cancer-free women who attended biennial health
examinations with a wide range of past radiation exposure levels (N = 412, ages 26–79). The
women were selected as controls for separate case-control studies from a cohort of A-bomb
survivors. Outcome measures included serum levels of total estradiol, bioavailable estradiol,
testosterone, progesterone, prolactin, insulin-like growth factor-1 (IGF1), insulin-like growth
factor-binding protein 3 (IGFBP-3), and ferritin. Relationships were assessed using repeatedmeasures regression models fitted with generalized estimating equations. Geometric mean serum
levels of total estradiol and bioavailable estradiol increased with 1 Gy of radiation dose among
samples collected from postmenopausal women (17%1Gy, 95% CI: 1%–36% and 21%1Gy, 95%
CI: 4%–40%, respectively), while they decreased in samples collected from premenopausal
women (−11%1Gy, 95% CI: −20%–1% and −12%1Gy, 95% CI: −20%– −2%, respectively).
Interactions by menopausal status were significant (P = 0.003 and P < 0.001, respectively).
Testosterone levels increased with radiation dose in postmenopausal samples (30.0%1Gy, 95% CI:
13%–49%) while they marginally decreased in premenopausal samples (−10%1Gy, 95% CI:
−19%–0%) and the interaction by menopausal status was significant (P < 0.001). Serum levels of
IGF1 increased linearly with radiation dose (11%1Gy, 95% CI: 2%–18%) and there was a
significant interaction by menopausal status (P = 0.014). Radiation-associated changes in serum
levels of estradiol, bioavailable estradiol, testosterone and IGF1 were modified by menopausal
status at the time of collection. No associations with radiation were observed in serum levels of
progesterone, prolactin, IGFBP-3 or ferritin.
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INTRODUCTION
Exposure to ionizing radiation via diagnostic imaging, particularly CT scans, continues to
increase worldwide 1. Numerous studies have proven the association between exposure to
ionizing radiation and breast cancer 2. Moreover, data from the A-bomb survivors indicate
that the breast is particularly susceptible to ionizing radiation exposure, with an attributable
fraction for breast cancer of 27% for all women exposed to more than 5 mGy 3 [a radiation
dose roughly twice the yearly background dose 4]. Breast cancer has also been associated
with levels of endogenous hormones, particularly estradiol (E2) 5–7. Estrogens stimulate
cell proliferation 8 and possibly exert a direct genotoxic effect on breast epithelial cells 9.
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Other circulating hormones and proteins, including non-sex hormone-binding globulin
(SHBG)-bound estradiol, testosterone 7 and insulin-like growth factor 1 (IGF1), have been
associated with breast cancer 10. Additional serum markers have been hypothesized to be
associated with breast cancer, including IGFBP-3 11, progesterone 12, prolactin 13 and
ferritin. Ferritin levels and ionizing radiation are associated with increased levels of free
radicals, and high ferritin levels have been reported to result in cell transformation and
immortalization in mammary glands 14.
The question of whether ionizing radiation exposure modifies the underlying levels of riskrelated circulating markers has not been addressed, however, and could be important in
mechanistic studies of breast cancer or other hormone-related cancers after ionizing
radiation exposure. The primary purpose of this project is to examine whether serum levels
of risk-related markers vary with past radiation exposure in a representative sample of
cancer-free female A-bomb survivors.

MATERIALS AND METHODS
Subjects
Study subjects were selected from the Adult Health Study (AHS), a longitudinal cohort
study of A-bomb survivors initiated in 1958 15. The AHS features biennial clinical
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examinations with serum collection and well-characterized radiation doses for numerous
body organs 16. Serum samples were selected in the context of concurrent case-control
studies wherein controls were selected by incidence density sampling from all subjects who
met eligibility requirements and were at risk for a first primary cancer of any type at the time
an index case was diagnosed. Eligibility was defined as women who were free from various
medical conditions (oophorectomy, current exogenous hormone treatment, prior
malignancies, pregnant), were cancer-free for at least 2 years after serum collection, and had
estimated radiation organ doses. Hormone-related diseases/conditions were based on selfreports or, in the case of extreme measured values, a medical chart review. Samples were
matched to an index case on age at collection (±2 years), sample collection year (same
decade), city (Hiroshima or Nagasaki), and counter-matched using breast radiation dose
strata (low, medium and high with cut-points at 5 mGy and 790 mGy) 17. Counter-matching
assures a wide exposure range while still providing an appropriate sample for inference of
the exposure effects within the underlying cancer-free cohort 18. Because it is not known
which organ system might be responsible for changes to serum markers, we used doses to
the colon for purposes of analyses. The colon is a centrally located organ, and colon doses
have been used as representative doses in other studies (e.g. for overall solid cancer risk
estimates), although the results should be relatively insensitive to the organ chosen since the
doses to all organs are highly correlated. Radiation doses to the colon were adjusted to
account for random errors in the individual radiation dose estimates 19. Menopausal status
at the time of sample collection was assigned using a two-step process. First, we used a
conservative age range to assign menopausal status. If a woman was less than 43 years of
age at the time of sample collection, she was designated premenopausal (N = 218); if she
was older than 55 years, she was designated postmenopausal (N = 139). For women in the
intermediate age group (43–55 years old), FSH (follicular stimulating hormone) levels were
measured and used to assign menopausal status primarily based upon the manufacturer's test
guidelines (premenopausal cutoff: FSH <=15 mIU/ml, postmenopausal cutoff: FSH >=23
mIU/ml) 20. Of those in the intermediate age range and assigned by FSH values (N = 152),
75 were designated premenopausal, 60 were postmenopausal, and the others were in
between the two cutoff values and were designated perimenopausal (N = 17). Due to the
paucity of samples collected from perimenopausal women, they were excluded. The final
data set included 492 samples collected from 412 women (293 premenopausal and 199
postmenopausal samples). Of the 80 subjects with two separate samples, 63 had samples that
were both collected prior to menopause, 6 subjects had samples that were both collected
after menopause, and 11 had one sample collected before and one after menopause.
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All blood samples were obtained with informed consent, and the Human Investigation
Committee of the Radiation Effects Research Foundation (RERF) approved the study
protocol.
Sample Storage and Serum Assays
Sera were collected in the Hiroshima and Nagasaki laboratories between 1969 and 1992 and
stored in vials at −80°C. Samples for this study were pulled from the freezers
simultaneously and assayed for total E2, bioavailable E2, testosterone, progesterone,
prolactin, IGF-1, IGFBP-3, ferritin, and total protein and protein fractions (albumin and
globulin). All assays were performed blinded to age, city of collection and radiation
exposure but were not performed in duplicate due to the limited serum amounts available.
Commercial laboratories with internal quality assurance systems performed all assays.
Supplementary Table 1 (http:dx.doi.org/10.1667/RR2631.1.S1) lists the assays and their
precision as reported by the kits' manufacturers.
Serum levels of IGF-1, IGFBP-3, FSH, prolactin, testosterone, progesterone and ferritin
were measured at a single laboratory (SRL Laboratory, Hachioji, Japan). Total protein
Radiat Res. Author manuscript; available in PMC 2014 February 17.

Grant et al.

Page 4

NIH-PA Author Manuscript

concentration and protein fractions were measured by SRL using the Biuret method and
cellulose acetate membrane electrophoresis, respectively. Serum levels of total E2 and
percentage bioavailable E2 were measured at a single laboratory (Mitsubishi Kagaku Bioclinical Laboratories, Tokyo, Japan). Percentage bioavailable E2 (the fraction of serum E2
that is free or loosely bound to albumin) was determined by ammonium sulfate precipitation
of SHBG-bound E2 21. Total E2 was multiplied by this percentage to obtain the
concentration of bioavailable E2. Serum ferritin was measured by the conventional
chemiluminescence enzyme immunoassay (CLEIA). When the aliquots of samples were
transported to outside laboratories for testing, they were packed in appropriate protective
shipping boxes with sufficient amounts of dry ice and checked at the time of receipt by the
measuring laboratories.
Methods of Analysis

NIH-PA Author Manuscript

Due to the skewed distributions of the markers, analyses were performed using logtransformed values for all of the markers except IGF1 and IGFBP-3, which did not require
transformation. Effects of radiation exposure were estimated with adjustment only for other
factors that were significantly related to marker level for statistical efficiency. Explanatory
factors considered were: age at time of sample collection, year of birth, menopausal status
(pre or post), total protein, body mass index [weight (kg)/height (m2)] and its square, history
of exogenous hormone use (yes or no), age at time of radiation exposure (including
dichotomy at 15 years as a surrogate for pre- or postmenarche at time of exposure), number
of full-term pregnancies, age at first full-term delivery, and radiation dose. Decisions for
inclusion of factors other than radiation dose were based on a backward selection process
where the least significant explanatory factor was removed until all factors were significant
at a level of P ≤ 0.05. The variable selection process was conducted separately for each
marker. Analyses were performed using a regression method for correlated (repeated)
measurements (generalized estimating equations; GEE) 22. P values and 95% confidence
intervals were based on the Wald statistic.
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Radiation effects were assessed using linear dose–response functions. Dose responses were
estimated with and without regard to effect modification by menopausal status at the time of
blood collection and ionizing radiation exposure before or after age 15. For markers that
were transformed prior to analyses, the radiation effects were reported on the untransformed
scale by exponentiating the regression coefficient obtained using the log-transformed data
and represent the association between 1 Gy radiation dose and the percentage change in
geometric mean of the marker level. IGF1 and IGFBP-3, which were not transformed, were
also reported on a relative scale by dividing the dose coefficient by the regression constant.
To test the strength of the observed radiation effects, we identified and removed the most
influential observations using the size-adjusted criterion 2/sqrt(n) for the t-statistic-like
standardized deletion diagnostic DFBETAS of Belsley et al. 23. To alleviate concerns about
misclassification of menopausal status at the time of sample collection due to possible
nonspecificity of the FSH results, we conducted a sub-analysis after restricting samples to
those collected from women at ages less than 43 or greater than 55 (135 samples omitted)
and compared results to the full analyses.
Statistical comparisons between samples collected pre- and postmenopause were performed
using χ2 tests (for counts), t tests for equality (for means) and Wilcoxon rank-sum tests for
independent samples (for medians). Interactions of radiation effects by menopausal status or
exposure before or after age 15 were tested using the likelihood ratio. To compare fits of
statistically significant non-nested interaction models, the quasi-likelihood/independence
criterion (QIC) was used 24. All results were obtained using Stata 25.
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Table 1 shows the demographics of the study cohort and marker values for samples
separated by menopausal status at the time of collection. The distribution of the radiation
dose is broader than what would be expected from a random sampling of all cancer-free
women since they were counter-matched (low, medium, high) against the dose status of the
case to ensure a broad representation of doses. The average year of sample collection is
somewhat later for postmenopausal samples because the AHS study is a fixed cohort; more
women were postmenopausal in later calendar years.
Table 2 shows the agreement of assays for the 63 pairs of samples collected from women
who were premenopausal at each collection. Comparisons of multiple samples collected
from the same women while postmenopausal were not reported (N = 6 pairs). The earlier
sample was collected at average age 39.7 years and the average interval between sample
collections was 2.8 years. Correlation coefficients ranged from 0.11 for progesterone to 0.75
for ferritin. A paired t test comparing the difference of the paired values with zero was not
significant for any marker except for serum prolactin, where the earlier value proved to be
significantly higher than the second value.
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The first column of Table 3 shows the associations of radiation with marker levels with no
allowance for effect modification but with adjustment for other significant factors. No
significant radiation associations were observed in any of the markers when ignoring
menopausal status. Columns two through five in Table 3 show the radiation associations
separately by menopausal status at the time of sample collection or by age at time of
bombing (≤15 or >15 years; ATB15). Because menopausal status at blood donation was
highly correlated with ATB15 in this study sample (particularly for a woman's first/only
serum sample), the latter two columns largely mirror the results displayed in the former two.
Total and bioavailable E2, testosterone and IGF-1 demonstrated statistically significant
associations with radiation dose in one or both periods.
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Total E2 (Fig. 1) decreased with radiation dose in the premenopausal period (relative change
0.89 at 1 Gy; 95% CI: 0.80, 0.99; P = 0.027), or in other words, the level of total E2 changed
as k*0.89dose, where k is the level of total E2 when the dose was zero (results from other
log-transformed variables are interpreted in the same way). The level of total E2 increased
with dose in the postmenopausal period (relative change 1.17 at 1 Gy; 95% CI: 1.01, 1.36; P
= 0.037). Effect modification by menopausal status was highly significant (P = 0.003) and
remained significant after removing the most influential values (P = 0.038). The association
of total E2 with radiation dose was similar when categorizing subjects based on ATB15
(rather than menopausal status at the time of collection); relative change for a 1-Gy dose at
age less than 15 years was 0.86 (95% CI: 0.76, 0.96; P = 0.010) and relative change for
exposure after age 15 was 1.12 (95% CI: 0.99, 1.26; P = 0.063). Models used to estimate the
radiation effects on total E2 included menopausal status, age at sample collection, total
protein, BMI and a BMI*postmenopause interaction. The QIC values for the two models
were very similar, but the value for the ATB15 interaction model was slightly lower (i.e.
better fit) than for the model with interaction by menopausal status.
The relative change is the percentage change at a dose of 1 Gy. The regression lines and P
values are based on the final models obtained for the markers (Table 3). The slopes of the
two regression lines by menopausal status are significantly different (P = 0.003).
Bioavailable E2 (Fig. 2) showed a significant decrease with radiation dose in the
premenopausal period, with a relative change of 0.88 at 1 Gy (95% CI: 0.80, 0.98; P =
0.022) and a significant increase with radiation dose in the postmenopausal period with a
relative change of 1.21 at 1 Gy (95% CI: 1.04, 1.40; P = 0.011). Effect modification by
Radiat Res. Author manuscript; available in PMC 2014 February 17.
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menopausal status was highly significant (P < 0.001) and remained so after exclusion of
influential observations (P = 0.003). As with total E2, bioavailable E2 also demonstrated
similar radiation effects according to whether exposure was before or after age 15 (0.87 at 1
Gy; 95% CI: 0.77, 0.98; P = 0.019 and a relative increase of 1.13 at 1 Gy; 95% CI: 1.00,
1.27; P = 0.045, respectively). The model used to estimate the radiation effects on
bioavailable E2 included menopause status, age at sample collection and total protein. Again
the QIC value was slightly lower for the model with ATB15 interaction.
The relative change is the percentage change at a dose of 1 Gy. The regression lines and P
values are based on the final models obtained for the markers (Table 3). The slopes of the
two regression lines by menopausal status are significantly different (P < 0.001).
Testosterone (Fig. 3) exhibited an increase with radiation dose in the postmenopausal period
(relative change 1.30 at 1 Gy; 95% CI: 1.13, 1.49; P < 0.001) and a marginally significant
decrease with radiation dose in the premenopausal period (0.90 at 1 Gy; 95% CI: 0.81, 1.00;
P = 0.049). Estimates of effect modification by menopausal status were highly significant
when estimates were derived using all observations (P < 0.001) and after excluding outliers
(P = 0.003), whereas no effect modification was evident with ATB15. The testosterone
model included menopause status, age at sample collection, total protein and a total
protein*postmenopause interaction, and BMI.
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The relative change is the percentage change at a dose of 1 Gy. The regression lines and P
values are based on the final models obtained for the markers (Table 3). The slopes of the
two regression lines by menopausal status are significantly different (P < 0.001).
IGF-1 (Fig. 4) displayed a significant increase with radiation dose in the premenopausal
period (relative change 1.11 per Gy; 95% CI: 1.02, 1.18; P = 0.024). Since the values from
this assay were not log-transformed, the results are interpreted as the percentage change in
marker levels per gray. No significant change with dose was observed in the
postmenopausal period (relative change 0.91 per Gy; 95% CI: 0.75, 1.04; P = 0.18). Similar
effects were seen when categorizing the women by age at exposure. Effect modification by
menopausal status was significant (P = 0.014) and remained so after removing the most
influential observations (P = 0.017). Comparing QIC values indicated that the model with
menopausal interaction model was preferable to the one with ATB15 interaction. Estimates
of the radiation effects were adjusted for age at sample collection, year of birth, total
protein*premenopause interaction, and number of full-term pregnancies.
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The relative change is the percentage change at a dose of 1 Gy. The regression lines and P
values are based on the final models obtained for the markers (Table 3). The slopes of the
two regression lines by menopausal status are significantly different (P = 0.014).
The other markers (IGFBP-3, progesterone, prolactin and ferritin) demonstrated no
associations with radiation dose, either with or without effect modification. No effect
modification of the radiation effects was observed in relation to the sample storage period,
time since exposure, or the number of full-term pregnancies, although E2 levels did increase
at a marginally significant level for each additional full-term pregnancy (results not shown).
Model fits generally improved when including the number of full-term pregnancies (as
either an effect modifier or a main effect), but the estimated coefficients for the number of
pregnancies were never statistically significant and therefore the results were not reported.
No improvements in model fit were detected by the addition of a quadratic dose term. Point
estimates were generally unchanged by the removal of samples retrieved when women were
aged 43 to 55.
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The present study was designed to investigate the associations of ionizing radiation exposure
with sex and growth hormones in cancer-free A-bomb survivors using stored sera.
Increasing levels of ionizing radiation exposure led to disparate changes by menopausal
status in a number of serum markers. Levels of E2 and bioavailable E2 increased in
postmenopausal samples while they decreased in premenopausal samples. Caution must be
used when interpreting the results in premenopausal samples, especially E2 levels, which are
highly variable in premenopausal women due to the menstrual cycle. Table 2 illustrates the
high variability of serum marker levels among premenopausal women. Controlling for the
day of the menstrual cycle was not possible, because the clinical examination protocol did
not attempt to record these values. It should be noted, however, that the point estimates for
the radiation findings were largely unchanged after separately removing the most influential
measurements (e.g., those associated with the E2 peak at ovulation) and excluding those in
the perimenopausal age range 43–55. Also, it is unlikely that there is any association with
the timing of blood sample collection and radiation dose, eliminating most concerns of
confounding. Nevertheless, chance findings for the premenopausal hormone associations
cannot be completely ruled out.
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The magnitude of change in total E2 levels was about 10% at 1 Gy of radiation (negative in
premenopausal women and positive in postmenopausal women). It is not clear that either of
these are clinically significant changes, particularly among premenopausal women where
there is so much variation. However, if E2 levels were assigned to quartiles in samples taken
from postmenopausal women, a 10% change in any particular result would generally be
sufficient to increase its quartile assignment by one category. Interpolating the results from
Fig. 1 of the meta-analysis performed by Key et al. 7, this increase in total E2 would roughly
correspond to a 25% increase in breast cancer risk.
The significance of IGF-1 and IGFBP-3 levels in pre- or postmenopausal breast cancer has
been under debate. The most recent evidence indicates that high levels of IGF-1 confer an
increased risk of breast cancer 10. In our study, radiation exposure appeared to increase the
level of IGF-1 in premenopausal women but had no effect on levels of IGF-1 in
postmenopausal women. Again, however, large variations were observed in the
premenopausal IGF-1 levels. IGFBP-3 was not associated with radiation exposure.
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If the results are correct, questions arise regarding the radiation-related biological pathways
that may affect sex hormone levels, particularly the most potent hormone E2. In
premenopausal women, E2 is produced primarily by the ovaries whereas after ovarian
involution, estrogen is primarily produced in adipose tissue by converting androgen to
estrogen via aromatase. A number of speculative mechanisms for an association between
radiation and sex steroid alterations can be suggested, including damage to primordial
ovarian follicles leading to decreased ovarian aromatase and depressed E2 production as
observed in the samples taken from women who were exposed at less than 15 years of age
26, 27. Ataya et al. reported similar findings with decreased ovarian size and long-term
decreased serum E2 levels in rhesus monkeys with ovarian exposure to ionizing radiation
28. Larsen et al. reported decreased ovarian volume in spontaneously ovulating women who
had received chemotherapy and radiotherapy for cancers diagnosed at mean age 5.4 years;
however, E2 levels were reported to be higher in those receiving (any type of) therapy
compared to a control group of similar age 29.
For the results seen among older birth cohorts (i.e. postmenopausal samples), radiationinduced upregulation of inflammatory cytokines, specifically TNFα, can lead to increased
estrogen biosynthesis 30–33; radiation can also alter lipid metabolism 34–36, possibly
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leading to hyperandrogenism through hypothalamus-pituitary-adrenal axis dysregulation 37.
Either of these latter mechanisms would be consistent with the observed increased E2 and
testosterone levels among the postmenopausal women.
No effect modification by the number of full-term pregnancies was evident in the radiation
effects on any of the markers. The number of women reporting any history of exogenous
hormone intake was less than 10%, and that variable was not a significant risk factor in any
of the tested models. Therefore, we do not believe that hormone treatment had a meaningful
impact on our findings. Interaction models categorizing exposures before or after age 15
more often had a better fit than models categorized by menopausal status at the time of
serum collection. However, this may be due to misclassification of menopausal status as
opposed to an important biological effect involving menarche status at the time of radiation
exposure. McDougall et al. found no association of breast cancer risk and menarche status at
the time of radiation exposure but did not consider serum marker levels 38.

NIH-PA Author Manuscript

Associations of radiation and markers modified by menopausal status were tested in the
results of eight bioassays (the two parallel analyses of modification by either menopause
status or ATB15 are effectively the same), which may raise concerns of finding associations
due to multiple testing. Using the conservative Bonferroni correction for multiple testing (α
= 0.05/8 = 0.00625), all of the tests for interaction remain significant with the exception of
IGF-1 (P = 0.014).
The study boasts a number of strengths, including well-characterized radiation doses to a
representative population of women, and data collected prospectively from cancer-free
women as part of a long-term follow-up regimen, including medical history data on
hormone-related conditions. However, there are also several weaknesses. The day of blood
collection in relation to the menstrual cycle was not available, which is problematic for
premenopausal estradiol measurements in particular. The use of FSH to assign menopausal
status has been shown to be not fully specific 39. It is also likely that misclassification
occurred when assigning menarche status by age. Due to the limited number of samples,
duplicate assays for quality control were not attempted. A limited number of women did
have multiple samples collected while premenopausal, for which the correlation between
marker assays was generally poor, probably due to different times in the menstrual cycle.
Despite these limitations, no major changes in the interactions between the measured
radiation associations and menopausal status were detected after separately removing the
most influential observations and those observations drawn from women in the
perimenopausal age range, which helps confirm the robustness of the associations.
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Conclusions
Previous studies have proven the potency of ionizing radiation as a carcinogen via direct
damage effects to DNA while separate lines of research have established serum levels of E2,
testosterone and IGF1 as risk factors for breast cancer. The results of this study suggest that
ionizing radiation may lead to changes in serum levels of cancer-related hormones and
proteins in cancer-free women and that these changes are dependent upon either the
menopausal status at the time of collection or the menarche status at the time of exposure.
Several mechanisms for these changes are suggested, but they are all speculative.
Researchers of cancer etiology after whole-body ionizing radiation exposure should be
aware of possible underlying changes in the levels of serum markers, which may confer
independent carcinogenic risks.
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FIG. 1.

Log total estradiol (E2) by menopausal status and radiation dose. The relative change is the
percentage change at a dose of 1 Gy. The regression lines and P values are based on the final
models obtained for the markers (Table 3). The slopes of the two regression lines by
menopausal status are significantly different (P = 0.003).
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FIG. 2.

Log bioavailable estradiol (E2) concentration by menopausal status and radiation dose. The
relative change is the percentage change at a dose of 1 Gy. The regression lines and P values
are based on the final models obtained for the markers (Table 3). The slopes of the two
regression lines by menopausal status are significantly different (P < 0.001).
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FIG. 3.

Log testosterone by menopausal status and radiation dose. The relative change is the
percentage change at a dose of 1 Gy. The regression lines and P values are based on the final
models obtained for the markers (Table 3). The slopes of the two regression lines by
menopausal status are significantly different (P < 0.001).
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FIG. 4.

IGF-1 by menopausal status and radiation dose. The relative change is the percentage
change at a dose of 1 Gy. The regression lines and P values are based on the final models
obtained for the markers (Table 3). The slopes of the two regression lines by menopausal
status are significantly different (P = 0.014).

NIH-PA Author Manuscript
Radiat Res. Author manuscript; available in PMC 2014 February 17.

NIH-PA Author Manuscript
2.53 (0.4–4.3)

IGFBP-3 (μg/ml)

Radiat Res. Author manuscript; available in PMC 2014 February 17.
39.48 (27.3–53.7)
15.7 (10 4–23.3)
1.60 (0.40–10.0)
6.20 (4.0–9.2)
21.50 (7.5–41.0)

Bioavailable E2 (pg/ml)

Testosterone (ng/dl)

Progesterone (ng/ml)

Prolactin (ng/ml)

Ferritin (ng/ml)

50.00 (29–94)

3.60 (2.4–5.1)

0.25 (0.19–0.30)

10.5 (6.7–18.3)

9.19 (5.6–13.2)

18.50 (13.1–25.2)

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

a

0.002
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0.267

0.472

<0.001

<0.001

0.036

c
25th percentile to the 75th percentile.

b
412 subjects (Hiroshima, N = 267/Nagasaki, N = 145). 80 subjects had multiple samples (63 subjects with two premenopausal samples, 6 subjects with two postmenopausal samples, 11 subjects with one
premenopausal sample and one postmenopausal sample).

Counts tested, with χ2 test for independence, means tested with t test for equality. medians tested with the Wilcoxon rank-sum test, for independent samples.

a

Notes. The upper section is the count of samples by city. The middle section shows the averages and ranges of non-transformed variables. The bottom section .shows the median and interquartile ranges of
natural log-transformed variables.
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57

IGFBP-3 (μg/ml)

2.51 (0.55)

129.0 (69.7)

3.12 (1.30)

1.86 (0.85)

0.49 (1.71)

2.74 (0.59)

3.65 (0.94)

4.47 (1.02)

Sample 1 average value (SD)

2.54 (0.43)

149 (67.9)

3.11 (1.35)

1.47 (0.61)

0.53 (1.64)

2.74 (0.59)

3.64 (0.54)

4.34 (0.54)

Sample 2 average value (SD)

0.36

0.16

0.75

0.28

0.11

0.52

0.16

0.14

Correlation

–0.029 (0.60)

–20.3 (88.1)

0.0082 (0.83)

0.39 (0.91)

–0.042 (2.3)

0.0066 (0.54)

0.014 (1.03)

0.13 (1.10)

Sample 1 – Sample 2 average value (SD)

0.96

0.19

0.93

0.001

0.54

0.55

0.42

0.10

P value

The average age at the time of Sample 1 collection was 37.9 years. and the average year of collection was 1970.9. The average age at the time of Collection for the second sample was 40.8 years and the
average year of collection was 1973.7. Values in parentheses (5D) after averages are standard deviations. The P value in the last column is a paired. t test (H0: Sample 1 – Sample 2 = 0).

Notes. Samples are confined to multiple premenopausal samples (there were only six persons who donated multiple postmenopausal samples).

57

IGF-1 (ng/ml)

Log progesterone (ng/ml)

56

54

Log testosterone (ng/dl)

51

57

Log bioavailable E2 (pg/ml)

Log ferritin (ng/ml)

63

Log total E2 (pg/ml)

Log prolactin (ng/ml)

N
63

Assayed biomarker

Comparison of Assay Values from Women Donating Multiple Samples
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Relative Radiation Associations with Adjusted Mean Marker Values and Effect Modification By Menopausal
Status and Age at Radiation Dose
Relative radiation
association at 1 Gy
no effect
modification (95%
confidence
intervals), P Value

Marker
b,d

Total E2

a
Relative radiation association at 1 Gy Separately by effect-modifier category (95%
confidence intervals). P value
Menopause status at time of sample
collection

Age at time of the bomb

Pre (N = 293)

Post (N = 199)

≤ 15 (N = 190)

>15 (N = 302)

0.97 (0.89, 1.06)

0.89 (0.80, 0.99)

1.17 (1.01, 1.36)

0.86 (0.76, 0.96)

1.12 (0.99, 1.26)

P = 0.52

P = 0.027

P = 0.037

P = 0.010

P = 0.063

Interaction P= 0.002*

Interaction P = 0.003
b,e

Bioavailable E2

0.98 (0.93, 1.06)

0.88 (0.80, 0.98)

1.21 (1.04, 1.40)

0.87 (0.77, 0.98)

1.13 (1.00, 1.27)

P = 0.84

P = 0.022

P = 0.011

P = 0.019

P = 0.045

Interaction P = 0.001*

Interaction P <0.001
bf
Testosterone ,
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1.02 (0.93, 1.12)

0.90 (0.81, 1.00)

1.30 (1.13, 1.49)

0.97 (0.84, 1.10)

1.06 (0.93, 1.20)

P = 0.70

P = 0.049

P < 0.001

P = 0.617

P= 0.387

Interaction P = 0.337

Interaction P < 0.001
bg
Progesterone ,

1.08 (0.90, 1.30)

1.08 (0.86, 1.35)

1.10 (0.81, 1.50)

1.00 (0.77, 1.29)

1.21 (0.93, 1.58)

P = 0.39

P = 0.52

P = 0.54

P = 0.992

P = 0.16

1.01 (0.91, 1.11)

0.97 (0.86, 1.09)

1.07 (0.91, 1.26)

0.94 (0.82, 1.08)

1.08 (0.95, 1.24)

P = 0.905

P = 0.641

P = 0.384

P = 0.413

P = 0.230

Interaction P = 0.905
bh
Prolactin ,

Interaction P = 0.313

Interaction P = 0.313
ci
IGF-1 ,

Interaction P = 0.161

1.04 (0.96, 1.10)

1.11 (1.02, 1.18)

0.91 (0.75, 1.04)

1.11 (0.99, 1.20)

0.98 (0.85, 1.07)

P = 0.29

P = 0.024

P = 0.18

P = 0.061

P = 0.850

Interaction P = 0.014*
cj
IGFBP-3 ,

Interaction P = 0.091

1 (0.97, 1.03)

1.01 (0.97, 1.05)

0.98 (0.92, 1.05)

1.00 (0.97, 1.04)

0.93 (0.97, 1.03)

P = 0.89

P = 0.48

P = 0.44

P = 0.81

P = 0.82

Interaction P = 0.28
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bk
Ferritin ,

Interaction P = 0.98

0.97 (0.83, 1.13)

0.98 (0.81, 1.18)

0.96 (0.73, 1.27)

0.87 (0.70, 1.09)

1.07 (0.86, 1.32)

P = 0.72

P = 0.81

P = 0.78

P = 0.22

P = 0.55

Interaction P = 0.92

Interaction P = 0.19

Notes. Numbers in parentheses art 95% confidence intervals. The first column shows the radiation associations without adjustment for menopause
status at the time of sample Collection or age at the time of the exposure from the atomic bombing. The right two sets of columns show the
radiation associations by menopause Status (columns 2, 3) and age less than or greater than 15 at the time of the bombing (columns 4, 5). The
“Interaction P” valuer test whether the results differ significantly by menopausal Status or age at the time of the bombing. Note that there were no
detected effects when effect modification was ignored. The models were developed using a backwards elimination process for statistical efficiency
as described in the text. Covariates for each model are listed in the footnotes. All effect modification models included the main effect variable
regardless of whether it was selected in the elimination process.
*

QIC value indicates that this interaction model was better than the alternative interaction model. This score was compared only between the two
interaction models and only when both models were significant.
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a

Effects of radiation are displayed separately for each of two categories of either menopausal status at time of Serum collection (pre- or
postmenopause) or age at time of exposure (up to age 15 or after aye 15). The main effect was always included when testing the interaction.
b

Log-transformed variable (relative change is calculated using Xdose, where X is the reported coefficient).
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c

Non-transformed variable (relative change is calculated using X * dose, where X is the reported coefficient).

d

Adjusted for age and menopause Status at sample collection, total protein, BMI and BMI*poslmenopause interaction.

e

Adjusted for age and menopause status at sample collection, total protein.

f

Adjusted for age and menopause status at sample collection, total protein, total protein*poslmenopause interaction, BMI.

g

Adjusted for menopause status at sample collection, total protein.

h

Adjusted for age and menopause status at sample collection.

i
j

Adjusted for age at sample Collection, year of birth, total protein*premenopause interaction, number of full-term pregnancies.
Adjusted for year of birth, total protein*premenopause interaction. BMI. BMI2.

k

Adjusted for age and menopausal status at sample collection, BMI, number of full-term pregnancies.
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